← Back to Clinical Trials
Recruiting NCT05881863

NCT05881863 To Investigate Airway Oxygen Concentrations During Rigid Bronchoscopy Procedures Performed With High Frequency Jet Ventilation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05881863
Status Recruiting
Phase
Sponsor University of Minnesota
Condition Central Airway Obstruction
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2024-01-12
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2024-01-12 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Thermal ablation (use of treatment modalities that generate heat) has become a widely used tool for treatment of central airway obstruction (e.g. laser, electrocautery, radiofrequency, and argon plasma coagulation). However, this method carries with it an increased risk for airway fire - a surgical fire that occurs in a patient's airway and could also include a fire in the attached breathing circuit. To decrease the risk of airway fire during mechanical ventilation with an endotracheal tube, the concentration of inspired oxygen (FiO2) is set below 40% while waiting for end tidal oxygen concentration (EtO2) to fall below 40% prior to starting thermal ablation. There is no published literature describing O2 concentration within the airways (AiO2) during jet ventilation with rigid bronchoscopy. The co-investigators of this study have recently collected data on AiO2 during rigid bronchoscopy using manual low frequency jet ventilation/high frequency jet ventilation with a period of apnea. The intent of this study is to measure the time taken for the central airway oxygen concentration to drop from 90 to 40% when the "laser mode" is activated on the Monsoon jet ventilator. Ventilation is continued during "laser mode."

Eligibility Criteria

Inclusion Criteria: * Patients undergoing rigid bronchoscopy for treatment of central airway obstruction at FV UMMC will be identified. * 18 years or older * Need rigid bronchoscopy as pre-determined by the interventional pulmonologist Exclusion Criteria: * Refusal to sign consent * Pregnant patients * Hemodynamic instability defined as continuous infusion of medication in order to support blood pressure and/or heart rate/rhythm * Respiratory instability defined as SpO2\<90% with \>90% supplemental oxygen. * Ineligible for rigid bronchoscopic intubation * Latex allergy * Evidence of fistulous airway * Active Bronchopleural fistula

Contact & Investigator

Central Contact

Candace Nelson

✉ nelso377@umn.edu
Principal Investigator

Sudarshan Setty, MD

PRINCIPAL INVESTIGATOR

University of Minnesota

Frequently Asked Questions

Who can join the NCT05881863 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Central Airway Obstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05881863 currently recruiting?

Yes, NCT05881863 is actively recruiting participants. Contact the research team at nelso377@umn.edu for enrollment information.

Where is the NCT05881863 trial being conducted?

This trial is being conducted at Minneapolis, United States.

Who is sponsoring the NCT05881863 clinical trial?

NCT05881863 is sponsored by University of Minnesota. The principal investigator is Sudarshan Setty, MD at University of Minnesota. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology